Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 301–400 of 1,002
Fan, L., Chen, J., Zhang, Q., Ren, J., Chen, Y., Yang, J., Wang, L., Guo, Z., Bu, P., Zhu, B., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02118-6 · Cited by 53
Fernandes, R., Jabbarizadeh, B., Rajeh, A., Hong, M. M. Y., Baines, K. J., Ernst, S., Winquist, E., Ali, A. S., Penny, S. L., Figueredo, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04183-8 · Cited by 56
“To contextualize these findings, we compared S. copri −response associations across three melanoma FMT trials 14,15,29 .”
InfluentialSelf-citationImmunotherapy for gastric cancer: a 2021 update.
Kole, C., Charalampakis, N., Tsakatikas, S. A., Kouris, N.-I., Papaxoinis, G., Karamouzis, M., Koumarianou, A., & Schizas, D. (2021) · Immunotherapy · doi:10.2217/imt-2021-0103 · Cited by 44
Woerner, J., Huang, Y., Hütter, S., Gurnari, C., Sánchez, J. M. H., Wang, J., Huang, Y., Schnabel, D., Aaby, M., Xu, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28678-x · Cited by 46
Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy
He, Y., Huang, J., Li, Q., Xia, W., Zhang, C., Liu, Z., Xiao, J., Yi, Z., Deng, H., Xiao, Z., et al. (2022) · Cancers · doi:10.3390/cancers14215317 · Cited by 50
Chen, Q., Wu, C., Xu, J., Ye, C., Chen, X., Tian, H., Zong, N., Zhang, S., Li, L., Gao, Y., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.01.013 · Cited by 50
Self-citationGut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Yan, J., Yang, L., Ren, Q., Zhu, C., Du, H., Wang, Z., Qi, Y., Xian, X., & Chen, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471273 · Cited by 56
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Vukadin, S., Khaznadar, F., Kizivat, T., Včev, A., & Smolić, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070835 · Cited by 49
“Recently, a published clinical study reported success in reverting anti-PD1 resistance in 6 out of 15 patients to whom respondent fecal microbiota transplantation was performed, linking the change in gut microbiota with response to anti-PD-1 therapy [97].”
BackgroundBacteria in cancer therapy: A new generation of weapons
Fan, J., Huang, Y., Li, Y., Muluh, T. A., Fu, S., & Wu, J. (2022) · Cancer Medicine · doi:10.1002/cam4.4799 · Cited by 46
Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans
Shtossel, O., Turjeman, S., Riumin, A., Goldberg, M. R., Elizur, A., Bekor, Y., Mor, H., Koren, O., & Louzoun, Y. (2023) · Microbiome · doi:10.1186/s40168-023-01623-w · Cited by 50
“PRJNA672867 Melanoma Response to PD-1 therapy 26 WGS [56]”
InfluentialHuman microbiome acquisition and transmission
Heidrich, V., Valles‐Colomer, M., & Segata, N. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01166-x · Cited by 56
Gut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
“…that FMT from prior anti-PD-1 responders can induce microbiome engraftment, reprogram the TME, and convert a subset of anti-PD-1–refractory patients to clinical benefit—providing proof-of-concept that altering microbial ecosystems can modulate antitumor immunity in humans [230, 264 [266].”
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
Gandini, A., Puglisi, S., Pirrone, C., Martelli, V., Catalano, F., Nardin, S., Seeber, A., Puccini, A., & Sciallero, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1161048 · Cited by 42
“These data suggest that FMT could represent a method to overcome resistance to ICIs in melanoma (93).”
MethodAntimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S. S., Liu, M., Liang, S., John, E. M., Gomez, S. L., Telli, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37636-0 · Cited by 49
Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
de Medeiros, M. C., The, S., Bellile, E. L., Russo, N., Schmitd, L. B., Danella, E. B., Singh, P. A., Banerjee, R., Bassis, C. M., Murphy, G. R., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01677-w · Cited by 50
“Fecal microbiome transplantation also reversed non-responsiveness to immune checkpoint inhibitors in patients with melanoma [16, 17].”
BackgroundZhu, X., Huang, X., Hu, M., Sun, R., Li, J., Wang, H., Pan, X., Ma, Y., Ning, L., Tong, T., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.03.002 · Cited by 43
Self-citationTabrizi, E., Tabrizi, F. P. F., Khaled, G. M., Sestito, M. P., Jamie, S., & Boone, B. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434771 · Cited by 46
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 67
“Fecal microbiota transplantation has been shown to enhance CD8 + T cell function [280] and reduce suppressive cell populations, such as MDSCs and Tregs, by modulating microbial-derived metabolites like short-chain fatty acids, potentially reversing ICI resistance [281].”
Modulating gut microbiota to treat cancer
Woelk, C. H., & Snyder, A. (2021) · Science · doi:10.1126/science.abg2904 · Cited by 42
The emerging potential ofmicrobiome transplantation on human health interventions
Junca, H., Pieper, D. H., & Medina, E. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.01.009 · Cited by 49
“622 that FMT changed the gut microbiome and reprogrammed the tumor microenvironment to overcome primary resistance to anti–PD-1 in a subset of patients with advanced melanoma [49,181].”
BackgroundDey, P., & Chaudhuri, S. R. (2022) · Biology · doi:10.3390/biology11050757 · Cited by 46
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
“Together with the ability of fecal microbiome transplantation (FMT) to overcome primary PD-1 resistance (51), they suggest that the early response is dominated by host-intrinsic and tumor-intrinsic factors but early nonresponse may be determined by the gut microbiota composition.”
BackgroundSelf-citationThe Evolving Landscape of Fecal Microbial Transplantation
Shao, T., Hsu, R., Hacein-Bey, C., Zhang, W., Gao, L., Kurth, M. J., Zhao, H., Shuai, Z., & Leung, P. S. C. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08958-0 · Cited by 48
Liu, N., Chen, L., Yan, M., Tao, Q., Wu, J., Chen, J., Chen, X., Zhang, W., & Peng, C. (2023) · Research · doi:10.34133/research.0127 · Cited by 41
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Bhamidipati, D., & Subbiah, V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.002 · Cited by 49
Tomita, Y., Sakata, S., Imamura, K., Iyama, S., Jodai, T., Saruwatari, K., Hamada, S., Akaike, K., Anai, M., Fukusima, K., et al. (2023) · Cancers · doi:10.3390/cancers16010047 · Cited by 48
“Notably, accumulating clinical evidence suggests that manipulating the gut microbiota through fecal microbiota transplantation (FMT) using stools from ICI-responsive patients enables patients with melanoma to overcome primary resistance to ICIs [19,20].”
BackgroundIsobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Murayama, M., Hosonuma, M., Kuramasu, A., Kobayashi, S., Sasaki, A., Baba, Y., Narikawa, Y., Toyoda, H., Isobe, J., Funayama, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59677-1 · Cited by 41
Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine
Meza‐Perez, S., Liu, M., Silva-Sánchez, A., Morrow, C. D., Eipers, P. G., Lefkowitz, E. J., Ptacek, T., Scharer, C. D., Rosenberg, A. F., Hill, D. D., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.06.003 · Cited by 44
Yang, Z., Ma, J., Han, J., Li, A., Liu, G., Sun, Y., Zheng, J., Zhang, J., Chen, G., Xu, R., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.002 · Cited by 50
Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.10.006 · Cited by 40
“…that bacteria-derived FLach peptides are constitutively present in CRs and may be involved in distribution across time points of this study, and FMT melanoma-ICI studies by (D) Davar et al., 2021, 10 (E) Baruchet al., 24 and (F) Routy et al. 13 and compared at differenttimepointsasindicated.”
Unveiling the intratumoral microbiota within cancer landscapes
Che, S., Yan, Z., Feng, Y., & Hai, Z. (2024) · iScience · doi:10.1016/j.isci.2024.109893 · Cited by 44
Zhou, Y., Han, W., Feng, Y., Wang, Y., Sun, T., & Xu, J. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5661 · Cited by 43
“Another study demonstrated that FMT altered the cellular constitution within the TME of patients with melanoma, helping to surmount resistance to anti‑PD‑1 therapy (60).”
BackgroundInfluence of the gut microbiota on immune cell interactions and cancer treatment
Liu, C., Fu, L., Wang, Y., & Yang, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05709-3 · Cited by 50
“Furthermore, even when administered via a single colonoscopy without antibiotic conditioning, FMT altered the microbiota composition for more than a year [64].”
BackgroundResultInfluentialA decade of advances in human gut microbiome-derived biotherapeutics
Pribyl, A. L., Hugenholtz, P., & Cooper, M. A. (2025) · Nature Microbiology · doi:10.1038/s41564-024-01896-3 · Cited by 52
“Both studies observed a benefit, with an improvement in clinical response in 20–30% of patients 34,35 , and demonstrated that changing the microbiome can overcome resistance to immunotherapy.”
The Mycobiome: Cancer Pathogenesis, Diagnosis, and Therapy
Gamal, A., Elshaer, M. Y. S., Alabdely, M. H., Kadry, A., McCormick, T. S., & Ghannoum, M. A. (2022) · Cancers · doi:10.3390/cancers14122875 · Cited by 45
“Furthermore, a recent clinical trial (NCT03341143) showed that FMT improved the response to anti-PD-1 therapy in melanoma patients [118].”
BackgroundShoji, F., Yamaguchi, M., Okamoto, M., Takamori, S., Yamazaki, K., Okamoto, T., & Maehara, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1040424 · Cited by 44
“In a recent study, FMT from ICI responders to ICI nonresponders produced ICI efficacy in melanoma patients (Davar et al., 2021).”
BackgroundThe Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy
Gholami, H., Chmiel, J. A., Burton, J. P., & Vareki, S. M. (2023) · Cancers · doi:10.3390/cancers15041300 · Cited by 43
“In 2021, two seminal clinical trials displayed that FMT from ICI responders with anti-PD1 therapy reprogrammed the tumor microenvironment to overcome resistance to PD1-blockade in a subset of melanoma patients [258,259].”
BackgroundWu, J., Dong, W., Pan, Y., Wang, J., Wu, M., & Yu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296783 · Cited by 52
Past, present, and future of microbiome-based therapies
Manrique, P., Montero, I., Fernández-Gosende, M., Martı́nez, N., Cantabrana, C. H., & Ríos-Covián, D. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2023.80 · Cited by 37
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.03.001 · Cited by 45
Gut Microbiota Modulation through Akkermansia spp . Supplementation Increases CAR T-cell Potency
Marcos-Kovandzic, L., Avagliano, M., Khelil, M. B., Srikanthan, J., Abdallah, R., Petrocelli, V., Rengassamy, J., Alfaro, A., Bied, M., Fidelle, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1230 · Cited by 45
Hadi, D. K., Baines, K. J., Jabbarizadeh, B., Miller, W. H., Jamal, R., Ernst, S., Logan, D., Bélanger, K., Esfahani, K., Elkrief, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012659 · Cited by 48
Self-citationBachem, A., Clarke, M. V., Kong, G., Tarasova, I., Dryburgh, L., Kosack, L., Lee, A. R., Newland, L. G. M., Wagner, T., Bawden, E., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.004 · Cited by 51
Schubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
Gut microbial metabolites in cancer therapy
Song, P., Peng, Z., & Guo, X. (2025) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.06.016 · Cited by 38
Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer
Montégut, L., de Cabo, R., Zitvogel, L., & Kroemer, G. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0504 · Cited by 38
Boesch, M., Horvath, L., Baty, F., Pircher, A., Wolf, D., Spahn, S., Straussman, R., Tilg, H., & Brutsche, M. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005401 · Cited by 38
CAR-T Cell Therapy and the Gut Microbiota
Asokan, S., Cullin, N., Stein‐Thoeringer, C. K., & Elinav, E. (2023) · Cancers · doi:10.3390/cancers15030794 · Cited by 42
“For example, two pilot first-in-human clinical trials recently provided evidence that melanoma immunotherapy responder-derived fecal microbiota transplantation (FMT) in combination with anti-PD-1 may benefit a subset of patients with PD-1-refractory melanoma [60,61].”
BackgroundApplication of emerging technologies for gut microbiome research
Kwa, W. T., Sundarajoo, S., Toh, K. Y., & Lee, J. W. J. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-432 · Cited by 43
“[40] Despite the non‐specific nature of the treatment, there has been an increasing number of FMT clinical trials conducted for other indications with considerable efficacy, such as for ulcerative colitis,[41] anticancer response to immune checkpoint inhibitors[42,43] as well as for type 2 diabetes mellitus.”
BackgroundCheng, S., Han, Z., Dai, D., Li, F., Zhang, X., Lu, M. S., Lü, Z., Wang, X., Zhou, J., Li, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101355 · Cited by 58
“18,19 In spite of these encouraging findings, microbiota signatures related to efficacy vary from different cohorts, 20 and this phenomenon may be attributed to the heterogeneity between tumor types and even within the same cancer type.”
BackgroundGriffith, B. D., & Frankel, T. L. (2024) · Cancers · doi:10.3390/cancers16030472 · Cited by 50
“This effect of the microbiome regulating the response to ICI therapy was further demonstrated in a phase II single-arm trial, where FMT partially reversed checkpoint inhibitor resistance in PD-1 refractory melanoma [142].”
Guevara‐Ramírez, P., Cadena-Ullauri, S., Paz‐Cruz, E., Ruiz‐Pozo, V. A., Tamayo‐Trujillo, R., Cabrera‐Andrade, A., & Zambrano, A. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910255 · Cited by 39
“Davar et al. (2021) demonstrated that FMT significantly enhanced therapy effectiveness in cancer patients who were previously non-responders, emphasizing the microbiota’s role in treatment response [171].”
BackgroundRahimi, A. R., Baghernejadan, Z., Hazrati, A., Malekpour, K., Samimi, L. N., Najafi, A., Falak, R., & Khorramdelazad, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118014 · Cited by 43
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 41
Chen, C., Su, Q., Zi, M., Hua, X., & Zhang, Z. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00818-3 · Cited by 51
“Initial clinical studies have shown promising results, such as over-coming resistance to anti-PD-1 antibodies in some patients with ICI-refractory metastatic melanoma through FMT from anti-PD-1-responsive donors 186,187 .”
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
“Neoadjuvant ICI: Stratification/early assessment of efficacy ctDNA MRD CheckMate-816 trial Forde PM, 2022 [251] Nivolumab + platinum-based CT or platinum-based CT alone, followed by resection NSCLC”
MethodComputational methods and challenges in analyzing intratumoral microbiome data
Wang, Q., Liu, Z., Ma, A., Li, Z., Liu, B., & Ma, Q. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.011 · Cited by 37
“Studies have showcased that fecal microbiota transplantation (FMT) promotes the immunotherapy response in refractory melanoma patients by modulating the gut microbiome [58,59].”
BackgroundMalard, F., Gaugler, B., & Mohty, M. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00223-x · Cited by 38
Wang, M., Zhang, L., Chang, W., & Zhang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096551 · Cited by 45
Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial
Rashidi, A., Ebadi, M., Rehman, T. U., Elhusseini, H., Kazadi, D., Halaweish, H., Khan, M. H., Hoeschen, A. L., Cao, Q., Luo, X., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2369 · Cited by 38
Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy
Deng, Y., Hou, X., Wang, H., Du, H., & Liu, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17050604 · Cited by 40
Self-citationThe emerging role of bacterial extracellular vesicles in human cancers
Liang, A., Korani, L., Yeung, C. L. S., Tey, S. K., & Yam, J. W. P. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12521 · Cited by 45
“Clinical trials have demonstrated its efficacy in overcoming resistance to anti-PD-1 treatment in melanoma (Baruch et al., 2021; Davar et al., 2021).”
BackgroundMicrobiota-mediated mechanisms of mucosal immunity across the lifespan
Iliev, I. D., Blander, J. M., Collins, N., Guo, C., Longman, R., Sonnenberg, G. F., Zeng, M. Y., & Artis, D. (2025) · Nature Immunology · doi:10.1038/s41590-025-02281-w · Cited by 66
“FMT trials indicate that microbiota-mediated responsiveness to ICI therapy in participants correlated with increased dendritic cell activation, T cell tumor infiltration and function, and remodeling of the myeloid compartment 208,209 .”
Wekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103025 · Cited by 46
Gopalakrishnan, V., Dozier, E. A., Glover, M. S., Novick, S. J., Ford, M. W., Morehouse, C. A., Warrener, P., Caceres, C. S., Hess, S. Y., Sellman, B. R., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071399 · Cited by 39
“More recently, positive outcomes have also been seen in the context of immune-checkpoint blockade therapies [5,6], even in patients who were historically refractory such therapies.”
BackgroundThe impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Guillot, N., Roméo, B., Manesh, S. S., Milano, G., Brest, P., Zitvogel, L., Hofman, P., & Mograbi, B. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.004 · Cited by 36
Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC
Yang, Y., Ye, M., Song, Y., Xing, W., Zhao, X., Li, Y., Shen, J., Zhou, J., Arikawa, K., Wu, S., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00785-9 · Cited by 36
“Furthermore, successful fecal microbial transplantation (FMT) can alter the gut microbiota pro fi le and reverse the resistance to ICIs in patients with melanoma 3,8,13,14 .”
Qu, Z., Tian, P., Yang, B. K., Zhao, J., Wang, G., & Chen, W. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120719 · Cited by 41
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 44
Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review
He, S., Lin, F., Hu, X., & Pan, P. (2023) · Nutrients · doi:10.3390/nu15224734 · Cited by 36
“FMT can effectively shift the intestinal microbiota composition toward taxa favoring anti-programmed death-1 (PD-1) efficacy which is associated with increased intra-tumoral and peripheral antitumor immunity [57,58].”
BackgroundResistance to immune checkpoint inhibitors in gastric cancer
Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 38
Exploring the role of gut microbiome in autoimmune diseases: A comprehensive review
Wang, H., Cai, Y., Wu, W. ‐., Zhang, M., Dai, Y., & Wang, Q. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103654 · Cited by 45
Self-citationPrognostic Biomarkers in Evolving Melanoma Immunotherapy
Reschke, R., Enk, A. H., & Hassel, J. C. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00910-y · Cited by 41
“Recent studies have demonstrated that fecal microbiota transplantation from responders can modify the gut micro-biome and reprogram the tumor microenvironment, potentially overcoming resistance to anti-PD-1 therapy [84, 85].”
Tong, J., Tan, Y., Ouyang, W., & Chang, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00636-5 · Cited by 47
“Clinical studies have demonstrated that fecal microbiota transplantation can reverse resistance to PD-1 inhibitors in melanoma patients [116].”
Runge, S., & Rosshart, S. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702378 · Cited by 41
The Role of Gut Microbiota in Tumor Immunotherapy
Wu, M., Bai, J., Ma, C., Wei, J., & Du, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/5061570 · Cited by 39
“By adjusting the intestinal microbiome, the tumor microenvironment is reprogrammed, and the resistance of PD-1 advanced melanoma to anti-PD-1 is overcome [59].”
BackgroundGut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy
Bozward, A. G., Ronca, V., Osei‐Bordom, D., & Oo, Y. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711217 · Cited by 40
McLean, A. E. B., Kao, S. C.-H., Barnes, D. J., WONG, K. K. H., Scolyer, R. A., Cooper, W. A., & Kohonen‐Corish, M. R. J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.011 · Cited by 38
Patient-derived cancer models: Valuable platforms for anticancer drug testing
Genta, S., Coburn, B. A., Cescon, D. W., & Spreafico, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976065 · Cited by 40
Lin, Z., Luo, M., Zhou, H., & Chen, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1068613 · Cited by 36
“A number of studies have illustrated that Ruminococcaceae and Lachnospiraceae families have been discovered to be related to the enhancement of immunological response (Davar et al., 2021), the improvement in renal function (Xu et al.”
BackgroundLiu, Y., Altreuter, J., Bodapati, S., Cristea, S., Wong, C. J., Wu, C. J., & Michor, F. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100444 · Cited by 48
“95,96 Studies that explored the gut microbiome’s effect on ICB efficacy in germ-free mice and patients found that Bacteroides thetaiotaomicron , Bacteroides fragilis , and members of the order Clostridiales were associated with anti-CTLA4 efficacy in melanoma and NSCLC, and the commensal genus…”
BackgroundMultimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer
Li, Y., Chang, R. B., Stone, M. L., Delman, D., Markowitz, K., Xue, Y., Coho, H., Herrera, V. M., Li, J. H., Zhang, L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101397 · Cited by 45
Targeting tumor metabolism to augment CD8+ T cell anti-tumor immunity
Liu, H., Yang, W., & Jiang, J. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101150 · Cited by 47
“Additionally, GLUT3, was also frequently upregulated in colorectal, breast, liver, gastric, and pancreatic cancers [52].”
Greathouse, K. L., & Choudhury, A. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.011 · Cited by 41
Lu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 45
Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096535 · Cited by 34
Microbiota-directed biotherapeutics: considerations for quality and functional assessment
Fekete, E. E. F., Figeys, D., & Zhang, X. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2186671 · Cited by 38
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331550 · Cited by 43
The link among microbiota, epigenetics, and disease development
El-Sayed, A., Aleya, L., & Kamel, M. S. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-13862-1 · Cited by 38
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
Zhou, C., Cheng, X., & Tu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.023 · Cited by 37
Tao, Y., Zhu, F., Pan, M., Liu, Q., & Wang, P. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.857370 · Cited by 46
Translating Microbiome Research From and To the Clinic
Zhang, Z. J., Lehmann, C. J., Cole, C. G., & Pamer, E. G. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041020-022206 · Cited by 33
Wan, L., Wu, C., Luo, S., & Xie, X. (2022) · Disease Markers · doi:10.1155/2022/3610038 · Cited by 42
Microbiome influencers of checkpoint blockade–associated toxicity
Wang, Y., Jenq, R. R., Wargo, J. A., & Watowich, S. S. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220948 · Cited by 37
Immunological consequences of microbiome-based therapeutics
Alam, M. Z., Maslanka, J. R., & Abt, M. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1046472 · Cited by 43
Advances in targeted therapy and immunotherapy for melanoma (Review)
Qin, Z., & Zheng, M. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12115 · Cited by 37
MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
Lee, P.-J., Hung, C.-M., Yang, A.-J., Hou, C.-Y., Chou, H.-W., Chang, Y.-C., Chu, W.-C., Huang, W.-Y., Kuo, W.-C., Yang, C.-C., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2380061 · Cited by 33
“…two studies reported that the clinical response rates were 30% (3 of 10) and 20% (3 of 15) in patients with refractory melanoma who were reintroduced to anti-PD1 therapy, 13,14 which were higher than that in patients who were retreated with anti-PD1 therapy alone (5 out of 34, 14.7%).”
BackgroundInfluentialSepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.